January 12, 2005 -- The Centient Biotech 200 managed a small gain on Wednesday, climbing 1.98 points (.06%) to 3384.68. Even though the rise was welcome, the move in the CBT 200 was less than the climb in the broad market. In individual company news, we discuss Myriad Genetics’ Alzheimer’s test, Paraxel’s upgrade, Cytrx’s scientific presentation, Dendreon’s further slide, and the probable break-up of the Mylan Labs-King Pharma marriage...
